A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies—including ovarian and uterine cancers—found a tolerable dosing schedule with promising activity, according to results reported by Dana-Farber Cancer Institute medical oncologist Dr. Elizabeth Lee at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

Learn how new research of the traces life-saving pediatric cancer treatments leave in DNA could help improve the detection and prevention of second neoplasms.

Phase I trial provides early clinical proof-of-concept supporting the combination of zedoresertib and lunresertib in certain advanced solid tumors

Zedoresertib, which targets WEE1, and lunresertib, a PKMYT1 inhibitor, are both investigational therapies that create synthetic lethality by blocking cell cycle proteins

Combination achieved notable responses in ovarian cancer at the preliminary recommended Phase II dose, with a 50% overall response rate across all patients and a 60% rate in patients with CCNE1 amplification

This combination has been granted FDA Fast Track Designation in patients with ovarian cancer harboring CCNE1 amplification, FBXW7 or PPP2R1A deleterious mutations